LabCorp’s Acquisition of Chiltern Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the Federal Trade Commission had granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or

LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer

Caveney is an Influential Thought Leader in Healthcare Financing, Regulatory Initiatives and Value-Based Care Models BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that Dr.

LabCorp Prices $600,000,000 in 3.250% Senior Notes Due 2024 and $600,000,000 in 3.600% Senior Notes Due 2027

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it has priced its offering of $1.2 billion in senior notes. The offering consists of two tranches: $600,000,000 aggregate principal amount of 3.250% Senior Notes due 2024 (the “2024 Notes”) and $600,000,000

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 15, 2017-- LabCorp® (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the “Notes”). The Notes will be senior unsecured obligations and will rank equally

LabCorp to Acquire Chiltern for Approximately $1.2 Billion in Cash, Advancing Its Leadership in Drug Development

LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance

Q2 Net revenue of $2.5 billion , up 5% over last year Q2 Diluted EPS of $1.82 , down 7% from last year; Q2 Adjusted EPS of $2.47 , up 5% over last year 2017 Adjusted EPS guidance increased to $9.30 to $9.65 , up 5% to 9% over 2016 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul.

LabCorp Introduces New ADAMTS13 Test for Rare Life-Threatening Blood Clot Disorder

LabCorp’s Proprietary Assay Offers Faster, More Accurate Diagnosis to Help Patients Receive Most-Appropriate Therapy BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 19, 2017-- LabCorp® (NYSE: LH) has begun offering its new, proprietary ADAMTS13 test to distinguish diseases characterized by

LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 18, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the National Evaluation System for health Technology Coordinating Center (NESTcc) has appointed William (Bill) Hanlon , Ph.D., chief development officer and head of

LabCorp and Novant Health Extend Laboratory Services Agreement

Extension Demonstrates Value of LabCorp’s Health System Collaborations BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 11, 2017-- LabCorp® (NYSE: LH) and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 3, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject